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Objective To evaluate the dose-response, efficacy, and safety of fluticasone furoate (FF; 25 mg, 50 mg, and 100 mg),
administered once daily in the evening during a 12-week treatment period to children with inadequately controlled
asthma.
Study design This was a Phase IIb, multicenter, stratified, randomized, double-blind, double-dummy, parallel-
group, placebo- and active-controlled study in children aged 5-11 years with inadequately controlled asthma. The
study comprised a 4-week run-in period, 12-week treatment period, and 1-week follow-up period. Children were
randomized to receive either placebo once daily, fluticasone propionate (FP) 100 mg twice daily, FF 25 mg, FF 50 mg,
or FF 100 mg each once daily in the evening. Primary endpoint was the mean change from baseline in daily morning
peak expiratory flow (PEF) averaged over weeks 1-12. Adverse events (AEs) also were investigated.
Results In total, 593 children were included in the intent-to-treat population. The difference vs placebo in change
from baseline daily morning PEF averaged over weeks 1-12 was statistically significant for the FF 25, FF 50,
FF 100, and FP 100 groups (18.6 L/min, 19.5 L/min, 12.5 L/min, and 14.0 L/min, respectively; P < .001 for all). The
incidence of AEs was greater in the FF groups (32%-36%) than in the placebo group (29%); the most frequent AE
was cough.
Conclusion FF and FP resulted in significant improvements in morning PEF compared with placebo, suggest-
ing that they are effective treatments for children with inadequately controlled asthma. All treatments were well tol-
erated; no new safety concerns were identified. (J Pediatr 2016;178:246-53).
Trial registration ClinicalTrials.gov: NCT01563029.
Inhaled corticosteroids (ICS) are considered the most effective anti-inflammatory treatments for all severities of persistentasthma.1-4 National and international guidelines advocate the use of ICS for reducing asthma symptoms and the risk of ex-acerbations in children aged 5-11 years with persistent asthma.1-3 Despite effective treatment being available, however, many
children with asthma remain uncontrolled. The Global Initiative for Asthma guidelines define uncontrolled asthma as having
≥3 of the following in the previous 4 weeks: daytime asthma symptoms >2 times per week; any night waking due to asthma;
the need for reliever for symptoms >2 times per week; or any activity limitation due to asthma.2 Low adherence has been pro-
posed as a potential contributing factor to uncontrolled asthma in children.5,6 In
addition, adherence to medications including ICS primarily has been shown to
decline as the number of doses per day increases,7,8 including in children with
asthma.9
AUC0-24 Area under the plasma-concentration curve over 0-24 hours
AE Adverse event
cACT childhood Asthma Control Test
FEV1 Forced expiratory volume in 1 second
FF Fluticasone furoate
FP Fluticasone propionate
ICS Inhaled corticosteroid
ITT Intent-to-treat
LOCF Last observation carried forward
MMRM Mixed modeling repeated measures
PAQLQ(S) Standardised Paediatric Asthma Quality of Life Questionnaire
PEF Peak expiratory flow
PK Pharmacokinetic
PP Per-protocol
SABA Short-acting beta2-agonist
UC Urinary cortisol
VI Vilanterol
From the 1Respiratory Therapy Area, GlaxoSmithKline,
Uxbridge, UK; 2Department of Pediatrics, National Jewish
Health, Denver, CO; 3Southern California Clinical Trials,
Newport Beach, CA; 4Pediatric Research Unit, Kolding
Hospital, University of Southern Denmark, Kolding,
Denmark; 5Departments of Pharmacy Practice and
Medicine, University of Wisconsin School of Medicine and
Public Health, Madison, WI; 6Clinica Ricardo Palma, San
Isidro, Lima, Peru; and 7Blizard Institute, Queen Mary
University London, London, UK
Funded by GlaxoSmithKline (GSK; 106855), which was
involved in the study design; the collection, analysis, and
interpretation of data; the writing of the report; and the
decision to submit the manuscript for publication. A.O.,
C.G., and S.T. are employees of and hold stocks/shares
in GSK. R.C. is supported by the National Heart Lung
Blood Institutes, GSK, Roche, and AstraZeneca and
serves as a consultant for GSK. J.G. has received
honoraria, travel, and accommodation expenses to attend
a GSK advisory board. S.P. has received lecture fees
from AstraZeneca and Boehringer Ingelheim and serves
as a consultant for GSK and Sandoz. The other authors
declare no conflicts of interest.
0022-3476/$ - see front matter. © 2016 GlaxoSmithKline. Published
by Elsevier Inc. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
http://dx.doi.org10.1016/j.jpeds.2016.08.010
www.jpeds.com • THE JOURNAL OF PEDIATRICSORIGINAL
ARTICLES
246
Fluticasone furoate (FF), delivered via the ELLIPTA inhaler
(GlaxoSmithKline, Hertfordshire, United Kingdom), is a novel
ICS that has been approved as a once-daily treatment of asthma
in adult and adolescent patients in the US.10 The purpose of
this study was to evaluate the dose-response, efficacy, and safety
of 3 doses of FF (25 mg, 50 mg, and 100 mg) administered once
daily in the evening during a 12-week treatment period to chil-
dren aged 5-11 years with inadequately controlled asthma.
Fluticasone propionate (FP) 100 mg was used as an active
comparator.
Methods
This was a Phase IIb, multicenter, stratified, randomized,
double-blind, double-dummy, parallel-group, placebo- and
active-controlled study (with rescue medication) in children
aged 5-11 years with inadequately controlled asthma
(ClinicalTrials.gov: NCT01563029 [106855]). The study con-
sisted of a 4-week run-in period, 12-week treatment period,
and 1-week follow-up period. During the run-in, children con-
tinued taking their current asthmamedication.All children were
provided with albuterol/salbutamol as needed for the relief of
asthma symptoms.
The original primary endpoint was change from baseline
in predose evening peak expiratory flow (PEF) at week 12, with
missing data for this endpoint assessment imputed by the use
of last observation carried forward (LOCF). This was changed
to the change from baseline in daily predose morning PEF av-
eraged over weeks 1-12 to use all available PEF data during
the treatment period, thereby requiring no imputation of
missing data. The endpoint also was changed for consistency
with the analysis of PEF in the adult FF/vilanterol (VI)
program.11,12 This change of endpoint was made at the time
of writing the reporting and analysis plan, before we unblinded
the database, and was approved by the European Medicines
Agency Paediatric Committee.
Eligible children were aged 5-11 years, had symptoms of
asthma at least 6 months before screening, and had been re-
ceiving short-acting beta2-agonist (SABA) alone, SABA with
a leukotriene modifying agent, or SABA with low-dose ICS
(≤250 mg FP) for ≥4 weeks before screening. Children also
had prebronchodilator PEF of 60%-90% of their best
postbronchodilator value, and, for those able to perform the
maneuver, demonstrated a ≥12% reversibility of forced expi-
ratory volume in 1 second (FEV1) within ~10-40 minutes fol-
lowing 2-4 inhalations of albuterol/salbutamol. Excluded
children had a history of life-threatening asthma; change in
asthma medication within 4 weeks of screening; an asthma ex-
acerbation (defined as a deterioration of asthma either re-
quiring the use of systemic corticosteroids for ≥3 days, or a
depot corticosteroid injection ≤3 months before screening, or
hospitalization or emergency department visit for asthma ≤6
months before screening); concurrent respiratory disease; or
any other clinically significant medical condition.
At the end of the run-in period, children eligible for ran-
domization had a prebronchodilator PEF of 60%-90% of their
best postbronchodilator value; symptoms of asthma (a score
of ≥1 on the daytime or nighttime asthma symptom scores re-
ported on the eDiary); and/or daily use of albuterol/salbutamol
on ≥3 of the last 7 consecutive days of the run-in period. In
addition, eligible children complied with the run-in medica-
tion on ≥4 of the last 7 consecutive days of the run-in period
and completed all questions on the eDiary on ≥4 of the 7 days
during the screening period. Children excluded from random-
ization had a change in asthma medication since screening;
an asthma exacerbation between screening and randomiza-
tion; or concurrent respiratory disease or any other clinically
significant medical condition.
The study was conducted in accordance with the ethical prin-
ciples outlined in the Declaration of Helsinki and was ap-
proved by the relevant ethics committee or institutional review
board at each investigational center.Written informed consent
was obtained from 2 parents/legal guardians. If applicable, the
child had to be able and willing to give assent to take part in
the study according to the local requirements. The investiga-
tor was accountable for determining a child’s capacity to assent.
Treatment and Assessments
Children were assigned randomly 1:1:1:1:1 to receive either
placebo via the ELLIPTA inhaler, FP 100 mg twice daily via the
DISKUS inhaler (GlaxoSmithKline), or FF 25 mg, FF 50 mg, or
FF100 mg eachoncedaily in the evening via theELLIPTA inhaler.
In addition, each received placebo twice daily via the DISKUS
inhaler, except for children in the FP 100 mg group, who re-
ceived placebo once daily via the ELLIPTA inhaler. Random-
ization was stratified by previous ICS therapy. Morning and
evening PEF weremeasured daily by the use of an eDiary with
a peak flow meter. FEV1 was measured in a subset of children
in the evening at clinic visits via an electronic spirometer, at
screening, randomization, and weeks 2, 4, 8, and 12.
Endpoints
The primary endpoint was the mean change from baseline in
daily predose morning PEF averaged over weeks 1-12. Sec-
ondary efficacy endpoints were change from baseline in: (1)
evening study visit trough FEV1 at the end of the treatment
period (using LOCF for imputation of missing postbaseline
FEV1 values); (2) percentage of rescue-free and symptom-
free days averaged over the treatment period; (3) daily predose
evening PEF averaged during the treatment period; (4) morning
and evening PEF over the last 7 days of the treatment period;
and (5) number of withdrawals due to lack of efficacy during
the treatment period. Withdrawal because of a lack of effi-
cacy was defined as reaching the PEF stability limit, use of
albuterol/salbutamol, experiencing a clinical asthma exacer-
bation, or worsening of asthma (defined as requiring treat-
ment other than study medication or use of rescue albuterol/
salbutamol, including nebulization). Other endpoints included
change from baseline in the childhood Asthma Control Test
(cACT) score at week 12 and change from baseline in the Stan-
dardised Paediatric Asthma Quality of Life Questionnaire, or
PAQLQ(S),13 score at week 12.
Pharmacokinetics (PK) blood samples were collected predose
and 20-40 minutes postdose at week 12. Plasma samples were
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analyzed for FF by mass spectrometry. The lower limit of quan-
tification was 10 pg/mL. The PK variables, maximum concen-
tration, and area under the plasma-concentration curve over
0-24 hours (AUC0−24) were assessed with PK analysis of the
plasma concentration-time data.
Safety and tolerability endpoints included: (1) the inci-
dence of adverse events (AEs) over weeks 1-12; (2) 24-hour
urinary cortisol (UC) excretion at baseline and week 12; (3)
laboratory assessments at screening and week 12 or early with-
drawal; (4) incidence of severe asthma exacerbations through-
out the treatment period; and (5) vital signs at randomization
and at weeks 2, 4, 8, and 12, or early withdrawal.
Statistical Analysis
With 575 children (115 children per treatment group) the study
had 90% power assuming a difference of 12 L/min in morning
PEF in the gatekeeper comparison between the average of the
greater 2 FF doses (FF 100 mg and FF 50 mg) and placebo, an
SD of 28 L/min, and significance declared at the 2-sided 5%
level. The study also had 90% power assuming a 12 L/min dif-
ference in morning PEF in the comparisons between any active
dose and placebo. To account for multiplicity across treat-
ment comparisons for the primary endpoint, comparisons of
each FF dose with placebo followed a step-down closed testing
procedure.
Provided the test of the average of the 2 greater FF doses
vs placebo was statistically significant, inference could be made
on comparisons of FF 100 mg vs placebo and FF 50 mg vs
placebo. Similarly, if both of these comparisons were statisti-
cally significant, inference could then be made on the com-
parison of FF 25 mg vs placebo with no further multiplicity
adjustment. For all efficacy and safety endpoints, the FP 100 mg
group was compared with placebo to provide a positive control
of relative efficacy.
The intent-to-treat (ITT) population comprised all chil-
dren randomized to treatment who received ≥1 study medi-
cation. The per-protocol (PP) population comprised all children
in the ITT population without any full protocol deviations.
The UC population consisted of children whose urine samples
had no confounding factors that would have affected the in-
terpretation of UC results. Finally, the PK population con-
sisted of children in the ITT population for whom a PK sample
was analyzed for FF. The population PK analysis included
concentration-time data from the current study combined with
data from 2 previous studies.14,15
The primary efficacy endpoint was analyzed with an analy-
sis of covariance model, allowing for the effects due to base-
line morning PEF, region, sex, actual prescreening ICS use, age,
and treatment group on the ITT and PP populations. Because
missing data were not imputed in this analysis, 5 sensitivity
analyses examined the impact of missing data: 1 mixed mod-
eling repeated measures (MMRM) analysis and 4 multiple im-
putation sensitivity analyses. The MMRM analysis accounted
for effects due to baseline morning PEF, region, sex, age, week,
and treatment group, including week-by-treatment and week-
by-baseline interaction terms. The other 4 imputation sensi-
tivity analyses used a Missing at Random approach, a Copy
Increment from Reference approach, a Jump to Reference ap-
proach, and a Copy Reference approach. All sensitivity analy-
ses examined an average treatment effect across the treatment
period. Three further supporting analyses were performed on
the primary endpoint: dose-response models, Bayesian analy-
ses with noninformative priors, and a MMRM model pre-
senting estimates from each week.
Statistical analyses for secondary endpoints were per-
formed with ANCOVA models with effects due to baseline,
region, sex, age, and treatment group. For the secondary end-
point of evening trough FEV1, an MMRM, and a Bayesian
analysis also were performed. The MMRM analysis was as per
the primary endpoint. The Bayesian analysis examined the pos-
terior probability distribution of the treatment differences of
each active treatment against placebo. For trough FEV1 and
morning and evening PEF at the endpoint, missing data were
imputed by use of the LOCF. Programming was performed with
SAS, version 9.1.3 (SAS Institute, Inc, Cary, North Carolina)
or later. Evaluation of percent predicted FEV1 values at base-
line were not prespecified in the protocol and are reported as
post hoc analyses.
Results
A total of 1540 children were screened, 596 children were ran-
domized with 593 (99.5%) children included in the ITT popu-
lation (Figure 1; available at www.jpeds.com). The study period,
from the first screening to the last visit, was fromMarch 2012
to September 2014. Demographics were generally similar
between treatment groups (Table I). There was a lower pro-
portion of children aged 5-7 years in the FF 50 mg treatment
group (26%) compared with the other treatment groups
(41%-47%). A total of 172 (29%) children withdrew during
the study (Figure 1), primarily due to lack of efficacy; the latter
was greater in the placebo group (35%) than in the FF groups
(14%-19%) and the FP group (16%).
Primary Endpoint
The adjusted treatment differences in the mean change
from baseline in daily predose morning PEF vs placebo were
18.6 L/min, 19.5 L/min, and 12.5 L/min for the FF 25 mg,
FF 50 mg, and FF 100 mg groups, respectively (Table II and
Figure 2; Figure 2 available at www.jpeds.com). In accor-
dance with the step-down closed testing procedure, all treat-
ment differences vs placebo were statistically significant
(P < .001; Table II). The analysis of the primary endpoint using
the PP population plus all sensitivity and supporting analy-
ses using the ITT population supported the findings of the
primary analysis. There was no apparent FF dose-ordering. The
adjusted treatment difference in the mean change from base-
line in morning PEF for FP 100 mg vs placebo also was statis-
tically significant (14.0 L/min; P < .001; Table II). When
stratified by prescreening ICS use, mean changes from base-
line inmorning PEF were greater for the active treatment groups
than placebo for children with prescreening ICS use and
without (Table II). Changes were similar regardless of
prescreening ICS use.
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Secondary Endpoints
The analysis of change from baseline in trough FEV1 at week
12 (LOCF) included 508 children (86%) in the ITT popula-
tion who provided technically acceptable FEV1 data16 both at
baseline and at least 1 postbaseline visit. There was a statisti-
cally significant adjusted treatment difference in the change
from baseline in trough FEV1 at week 12 (LOCF) for the
FF 25 mg group compared with placebo (126 mL, P < .001) but
not for the other treatment comparisons (Table II). The results
of theMMRM analysis supported the findings of the ITT analy-
sis; however, in a post hoc analysis including only children with
acceptable FEV1 measurements, all treatment groups demon-
strated numerically greater changes from baseline vs placebo
(Table III; available at www.jpeds.com). A further post hoc
analysis of FEV1 data by age subgroup was performed because
of statistically significant interactions between treatment and
age in theMMRM analysis. The change from baseline in trough
FEV1 for children aged 5-7 years was similar for all groups, in-
cluding placebo (Table III). However, in children aged 8-11
years, the change from baseline in trough FEV1 was greater than
placebo for all active treatment groups (Table III).
During the treatment period, notable differences from base-
line in percentage of rescue-free days were observed for all FF
groups compared with placebo. These differences were statis-
tically significant in the FF 50 mg and FF 100 mg groups (9.8%,
P = .023 and 12.2%, P = .004, respectively), and equated to an
additional 0.7 and 0.9 rescue-free days per week, respectively
(Table II). For symptom-free days, small increases were ob-
served in all groups including placebo and so statistically sig-
nificant differences vs placebo were not reached in any
treatment group (Table II).
For all secondary PEF endpoints, FF treatment led to sta-
tistically significant improvements compared with placebo
(except for change from baseline in evening PEF at week 12
[LOCF] for the FF 100 mg group, P = .266), although no dose
ordering was observed (Table II). The proportion of with-
drawals due to lack of efficacy over weeks 1-12 were statisti-
cally significantly lower in all FF groups (14%-19%) and
the FP 100 mg group (16%) compared with placebo (35%;
Table II).
Other Endpoints
Improvements from baseline to week 12 were observed for both
cACT score and total PAQLQ(S) score in all active treatment
groups and placebo (Table II). Adjusted treatment differ-
ences vs placebo were not statistically significant with FF for
change in baseline cACT score or total PAQLQ(S) score analy-
ses (Table II).
Table I. Summary of demographic characteristics and baseline characteristics
Number (%) subjects
Placebo,
N = 119
FF 25 OD,
N = 118
FF 50 OD,
N = 120
FF 100 OD,
N = 118
FP 100 BD,
N = 118
Total
N = 593
Sex, n (%)
Female 49 (41) 41 (35) 46 (38) 48 (41) 39 (33) 223 (38)
Male 70 (59) 77 (65) 74 (62) 70 (59) 79 (67) 370 (62)
Age, y
Mean (SD) 8.0 (1.9) 7.9 (2.1) 8.4 (1.6) 7.8 (2.0) 7.9 (1.9) 8.0 (1.9)
Age group, n (%)
5-7 y 49 (41) 48 (41) 31 (26) 55 (47) 51 (43) 234 (39)
8-11 y 70 (59) 70 (59) 89 (74) 63 (53) 67 (57) 359 (61)
Race, n (%)
White 48 (40) 57 (48) 51 (43) 52 (44) 43 (36) 251 (42)
White and American Indian or Alaskan Native 33 (28) 33 (28) 39 (33) 38 (32) 40 (34) 183 (31)
American Indian or Alaskan Native 24 (20) 17 (14) 16 (13) 17 (14) 21 (18) 95 (16)
African American or African heritage 4 (3) 4 (3) 7 (6) 8 (7) 7 (6) 30 (5)
Asian 8 (7) 7 (6) 6 (5) 2 (2) 7 (6) 30 (5)
Other 10 (8) 7 (6) 7 (6) 3 (3) 7 (6) 34 (6)
Ethnicity, n (%)
Hispanic/Latino 64 (54) 55 (47) 57 (48) 60 (51) 65 (55) 301 (51)
Not Hispanic/Latino 55 (46) 63 (53) 63 (53) 58 (49) 53 (45) 292 (49)
Duration of asthma, n (%)
<1 y 8 (7) 5 (4) 9 (8) 6 (5) 7 (6) 35 (6)
≥1 to <2 y 15 (13) 22 (19) 14 (12) 14 (12) 15 (13) 80 (13)
≥2 to <5 y 44 (37) 40 (34) 45 (38) 53 (45) 49 (42) 231 (39)
≥5 to <10 y 49 (41) 49 (42) 50 (42) 44 (37) 45 (38) 237 (40)
≥10 y 3 (3) 2 (2) 2 (2) 1 (<1) 2 (2) 10 (2)
Baseline lung function test results
Mean prebronchodilator PEF (SD), L/min 192.5 (67.1) 193.3 (60.8) 198.1 (54.0) 180.4 (59.8) 182.9 (57.2) 189.5 (60.1)
Mean percentage of pre- to postbronchodilator PEF (SD), % 79.4 (8.4) 79.3 (7.9) 78.5 (8.0) 77.9 (8.8) 79.0 (8.0) 78.8 (8.2)
Baseline FEV1, L (SD) 1.39 (0.46) 1.44 (0.40) 1.44 (0.42) 1.31 (0.41) 1.33 (0.45) 1.38 (0.43)
Prebronchodilator FEV1, % predicted*
n 114 104 115 108 111 552
Mean (SD) 84.4 (19.7) 84.8 (17.6) 84.1 (17.2) 82.1 (17.7) 82.5 (18.9) 83.6 (18.2)
Baseline patient-reported outcomes
Mean cACT score (SD) 17.8 (3.9) 18.4 (4.2) 17.7 (4.1) 17.4 (4.0) 18.0 (4.3) -
BD, twice daily; OD, once daily.
*% predicted FEV1 data are post hoc analyses.
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Table II. Primary, secondary, and other endpoints
Placebo,
n = 119
FF 25 OD,
n = 118
FF 50 OD,
n = 120
FF 100 OD,
n = 118
FP 100 BD,
n = 118
Primary endpoint
Mean change from baseline in daily morning PEF (L/min), weeks 1-12
n 119 117 118 118 117
LS mean 198.9 217.5 218.4 211.3 212.9
LS mean change (SE) 3.3 (2.6) 21.9 (2.7) 22.8 (2.7) 15.8 (2.6) 17.3 (2.6)
Treatment vs placebo
Difference, L/min 18.6 19.5 12.5 14.0
95% CI 11.3, 26.0 12.1, 26.9 5.1, 19.8 6.7, 21.4
P value <.001 <.001 <.001 <.001
Mean change from baseline in daily morning PEF (L/min), weeks 1-12 by
prescreening ICS use
Prescreening ICS used
n 65 62 65 62 63
Mean (SD) 1.2 (33.6) 21.3 (25.4) 22.3 (37.0) 15.5 (25.2) 20.5 (29.13)
No prescreening ICS used
n 54 55 53 56 54
Mean (SD) 4.3 (23.6) 16.1 (38.7) 24.2 (32.8) 19.1 (32.1) 17.7 (26.0)
Secondary endpoints
Change from baseline in evening trough FEV1, week 12 (LOCF)
n 102 96 112 96 102
LS mean, L 1.524 1.650 1.545 1.557 1.587
LS mean change, mL (SE) 128 (26) 254 (27) 150 (25) 162 (27) 192 (26)
Treatment vs placebo
Difference, mL 126 22 33 64
95% CI 51, 201 −50, 94 −41, 108 −10, 137
P value <.001 .551 .379 .089
Change from baseline in percentage of rescue-free days, weeks 1-12
n 119 117 118 118 117
LS mean change (SE) 16.5 (3.0) 24.9 (3.0) 26.3 (3.0) 28.7 (3.0) 22.7 (3.0)
Treatment vs placebo
Difference 8.4 9.8 12.2 6.2
95% CI 0.0, 16.9 1.3, 18.2 3.8, 20.5 −2.1, 14.6
P value .050 .023 .004 .143
Change from baseline in percentage of symptom-free days, weeks 1-12
n 119 117 119 118 117
LS mean change (SE) 19.0 (2.9) 21.0 (2.9) 24.7 (2.9) 22.9 (2.9) 22.0 (2.9)
Treatment vs placebo
Difference 2.1 5.8 3.9 3.0
95% CI −6.1, 10.2 −2.3, 13.9 −4.1, 12.0 −5.0, 11.1
P value .619 .161 .340 .459
Change from baseline in evening PEF (L/min), weeks 1-12
n 119 117 119 118 117
LS mean 210.3 221.5 223.7 218.7 218.3
LS mean change (SE) 5.1 (2.8) 16.3 (2.8) 18.5 (2.8) 13.5 (2.8) 13.1 (2.8)
Treatment vs placebo
Difference, L/min 11.2 13.4 8.4 8.0
95% CI 3.4, 19.0 5.7, 21.1 0.7, 16.1 0.3, 15.7
P value .005 <.001 .033 .042
Change from baseline in morning PEF (L/min), week 12 (LOCF)
n 119 117 118 118 117
LS mean 198.3 218.9 216.1 209.8 214.9
LS mean change (SE) 2.7 (3.8) 23.3 (3.9) 20.6 (3.8) 14.2 (3.8) 19.3 (3.8)
Treatment vs placebo
Difference, L/min 20.6 17.9 11.5 16.7
95% CI 10.0, 31.3 7.2, 28.6 0.9, 22.1 6.0, 27.3
P value <.001 .001 .033 .002
Change from baseline in evening PEF (L/min), week 12 (LOCF)
n 119 117 118 118 117
LS mean 210.3 221.5 223.4 216.2 216.5
LS mean change (SE) 5.0 (3.8) 16.2 (3.8) 18.2 (3.8) 11.0 (3.8) 11.3 (3.8)
Treatment vs placebo
Difference, L/min 11.2 13.1 5.9 6.2
95% CI 0.7, 21.7 2.6, 23.6 −4.5, 16.3 −4.2, 16.6
P value .037 .014 .266 .242
Number of withdrawals due to lack of efficacy throughout the 12-wk treatment period
n (%) 42 (35) 16 (14) 23 (19) 21 (18) 19 (16)
Treatment vs placebo
P value <.001 .006 .003 <.001
(continued)
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Pharmacokinetics
Concentration-time data for FF from this study were merged
with data from 2 previous studies in children aged 5-11 years
with FF 100 mg once daily alone14,15 or in combination with
VI.15 The resulting population PK dataset comprised 306
children. The predicted mean FF maximum concentration
(95% CI) for children in the current study was 5.7 pg/mL
(5.1-6.4), 11.6 pg/mL (10.6-12.7), and 22.4 pg/mL (19.9-
25.3) for the FF 25 mg, FF 50 mg, and FF 100 mg groups,
respectively. The predicted mean FF AUC0-24 (95% CI)
for children in the current study was 47 pg.h/mL (41-54),
98 pg.h/mL (87-110), and 196 pg.h/mL (167-230) for the
FF 25 mg, FF 50 mg, and FF 100 mg groups, respectively.
Safety
The incidence of AEswas slightly greater in the FF groups (32%-
36%) than in the placebo group (29%), but there was no ap-
parent dose-ordering (Table IV). The most frequent AE was
cough (Table IV). Four children experienced 4 AEs consid-
ered to be related to study treatment. These were pharyngitis
and cough, reported for 1 child each in the placebo group; 1
child with cough in the FF 25 mg group; and 1 child with sto-
matitis in the FF 100 mg group (Table IV). Two on-treatment
nonfatal serious AEs were reported; 1 event of syncope
(FF 50 mg group) and 1 event of hepatitis A (FF 100 mg group)
(Table IV).Neither was considered to be related to study treat-
ment. Asthma exacerbations were experienced by 12 children
Table II. Continued
Placebo,
n = 119
FF 25 OD,
n = 118
FF 50 OD,
n = 120
FF 100 OD,
n = 118
FP 100 BD,
n = 118
Other endpoints
Change from baseline in cACT score, week 12
n 70 97 89 84 89
LS mean change (SE) 3.7 (0.4) 4.0 (0.3) 4.4 (0.4) 3.5 (0.4) 4.1 (0.3)
Treatment vs placebo
Difference 0.2 0.7 −0.2 0.3
95% CI −0.8, 1.3 −0.4, 1.7 −1.3, 0.8 −0.7, 1.4
P value .637 .198 .696 .518
Change from baseline in total PAQLQ(S) score, week 12
n 52 61 71 57 64
LS mean change (SE) 0.8 (0.1) 0.9 (0.1) 0.9 (0.1) 1.0 (0.1) 1.1 (0.1)
Treatment vs placebo
Difference 0.1 0.1 0.2 0.3
95% CI −0.2, 0.4 −0.1, 0.4 −0.1, 0.5 0.0, 0.6
P value .423 .349 .112 .036
LS, least squares.
Table IV. Most frequent (≥3% in any treatment group) on-treatment AEs by preferred term (ITT population)
AEs
Number (%) subjects
Placebo, n = 119 FF 25 OD, n = 118 FF 50 OD, n = 120 FF 100 OD, n = 118 FP 100 BD, n = 118
Children with any AE 35 (29) 43 (36) 38 (32) 39 (33) 36 (31)
Children with most frequent events 28 (24) 30 (25) 25 (21) 31 (26) 26 (22)
Cough 6 (5) 7 (6) 1 (<1) 10 (8) 5 (4)
Nasopharyngitis 4 (3) 9 (8) 4 (3) 3 (3) 4 (3)
Rhinorrhea 2 (2) 6 (5) 1 (<1) 6 (5) 5 (4)
Pharyngitis 4 (3) 2 (2) 7 (6) 5 (4) 1 (<1)
Headache 2 (2) 2 (2) 2 (2) 7 (6) 4 (3)
Oropharyngeal pain 1 (<1) 6 (5) 2 (2) 2 (2) 4 (3)
Bronchitis 1 (<1) 2 (2) 4 (3) 2 (2) 2 (2)
Upper respiratory tract infection 3 (3) 1 (<1) 0 (0) 4 (3) 3 (3)
Pyrexia 0 (0) 4 (3) 1 (<1) 2 (2) 1 (<1)
Body temperature increased 0 (0) 3 (3) 0 (0) 0 (0) 4 (3)
Rhinitis 3 (3) 1 (<1) 1 (<1) 0 (0) 2 (2)
Tonsillitis 3 (3) 1 (<1) 2 (2) 1 (<1) 0 (0)
Viral infection 2 (2) 0 (0) 3 (3) 1 (<1) 1 (<1)
Dyspnea 3 (3) 0 (0) 0 (0) 1 (<1) 0 (0)
Respiratory tract infection 0 (0) 3 (3) 0 (0) 0 (0) 1 (<1)
Children with treatment-related AEs 2 (2) 1 (<1) 0 1 (<1) 0
Cough 1 (<1) 1 (<1) 0 0 0
Stomatitis 0 0 0 1 (<1) 0
Pharyngitis 1 (<1) 0 0 0 0
Children with treatment-related serious AEs 0 0 0 0 0
Children with nonfatal serious AEs
Syncope 0 0 1 (<1) 0 0
Hepatitis A 0 0 0 1 (<1) 0
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during the treatment period (7 [6%] children in the placebo
group, 2 [2%] children in each of the FF 25 mg and FF 50 mg
groups, and 1 [1%] in the FF 100 mg group). None of these
children were hospitalized, but all were withdrawn from the
study. Vital signs at baseline and changes from baseline at all
recorded time points were similar between treatment groups.
In the UC population, 1 child had a 24-hour UC excretion
at week 12 of 1054.4 nmol/24 hour (Figure 3; available at
www.jpeds.com). The child had not received any additional
glucocorticoids, and findings of the clinical examination of the
child were unremarkable. As such, this value was considered
an outlier because of technical error and not included in the
primary analysis of 24-hour urinary excretion (Figure 3 and
Table V; Table V available at www.jpeds.com). The analyses
with the outlier removed were not prespecified in the proto-
col and are reported as post hoc analyses.Adjusted ratio to base-
line values for 24-hour UC excretion were 1.07 (n = 54) for
placebo, 0.95-1.00 (n = 72-75) for the FF treatment groups, and
0.96 (n = 73) for the FP group. Treatment ratios to placebo were
0.89, 0.94, and 0.90, for the FF 25 mg, FF 50 mg, and FF 100 mg
groups, respectively, and there were no statistical differences
between any of the FF groups and placebo.
Laboratory assessments were within the normal range at
screening and week 12 except for serum carbon dioxide content
values, which were below the normal range for the majority
of children across all treatment groups both at baseline and
at week 12 (56%-72%).
Discussion
In this study, all active treatments (FF and FP) resulted in clini-
cally and statistically significant improvements in the mean
change from baseline in morning PEF compared with placebo;
however, there was no apparent dose-ordering effect in the FF
treatment groups. The doses of FF used in our study were based
on data from a dose-ranging study in adults and adolescents17
and a repeat-dose study in children.14 The lack of dose-
ordered response was consistent with the findings of other
studies that assessed lung function response to ICS both in adult
patients18 and children.19
Although spirometry is a robust measure of lung function
and can be performed in young children given encourage-
ment and suitable conditions, in clinical practice this requires
experienced specialist staff and cooperation fromboth theparent
and child. Therefore, PEF was chosen as the primary end-
point because it is easier for children to perform than FEV1.20
Compared with other studies of ICS in children, the treat-
ment differences in mean change from baseline in morning
PEF reported here (12.5-19.5 L/min) show a similar level
of improvement. For example, in a randomized trial of
FP 50 mg and FP 100 mg in children aged 4-11 years, the mean
change from baseline in morning PEF ranged from 48 L/min
to 51 L/min compared with 22 L/min in the placebo group
(P ≤ .05).21 Furthermore, in a randomized trial in children, the
approved ICS beclomethasone dipropionate 160 mg/d re-
sulted in amean change frombaseline inmorningPEFof 30.8 L/
min comparedwith 9.2 L/min in the placebo group (P ≤ .01).22
The PEF results in our study demonstrate a positive treat-
ment effect on lung function; however, the effect on FEV1 is
less clear. Although FF treatment resulted in an increase from
baseline of between 150 mL and 254 mL at week 12, this was
not significantly different from placebo for the 50 mg and 100 mg
FF groups, mainly because of the pronounced placebo re-
sponse. The increase in FEV1 vs placebo was notably greater
for the FF 25 mg treatment than the other FF doses and the
FP 100 mg treatment. The reason for this is unclear, but because
all 3 FF doses were effective on PEF, it is possible this obser-
vation is due in part to the difficulty in obtaining good quality
spirometry in children. This is supported by the post hoc analy-
ses of FEV1 by age and acceptable FEV1 measurements.
Secondary endpoints generally supported the primary end-
point result. In particular, the assessed patient-reported out-
comes suggested a favorable effect of FF treatment, with an
additional 0.7 and 0.9 rescue-free days per week observed for
FF 50 mg and FF 100 mg, respectively. Interestingly however,
statistical significance was not reached for the change from base-
line in percentage of symptom-free days over weeks 1-12. The
relationship between asthma control and symptoms in chil-
dren is complicated because better control often leads to an
increase in physical activity.23
A greater proportion of children withdrew from the study
because of a lack of efficacy in the placebo group (35%) than
in the FF groups (14%-19%) and the FP group (16%). This
finding suggests that, despite the modest effects on lung func-
tion, FF was a beneficial treatment in the current study.With-
drawal rates for children receiving active treatment were similar
to those observed in previous studies of children with asthma
receiving ICS treatment (10%-30%).24
In the PK analysis, a large number of FF plasma samples
were below the lower limit of quantification; therefore, data
from the current study were merged with historical data from
FF 100 mg pediatric studies. Systemic exposure of FF over
the dose range assessed was generally low and approximately
dose-proportional. Peak FF plasma concentrations from
the current study (22.4 pg/mL) were similar to those values
estimated in children receiving FF 100 mg (24.68 pg/mL)14 or
FF/VI 100/25 mg (20.7 pg/mL).15 The rate and extent of ex-
posure of FF at steady state in children in the current study
following FF 100 mg also was consistent with that observed in
adults and adolescents (AUC(0−24) of 196 pg.h/mL compared
with 181 pg.h/mL, respectively).25
Once-daily treatment with FF was well tolerated at all doses.
The overall incidence of AEs was similar across the FF treat-
ment groups and the FP 100 mg group and was slightly greater
for the FF and FP groups compared with placebo. The most
common on-treatment AEs in all treatment groups (cough,
nasopharyngitis, and rhinorrhea) are commonly observed in
an asthmatic population. No clinically significant UC sup-
pression was observed at week 12.
Some important features of the study include the large
number of children recruited, the opportunity to assess 3 doses
of FF, and the inclusion of a positive (FP) and negative (placebo)
control; however, the difficulty in recruiting children with poorly
controlled asthma, and in coaching good-quality spirometry
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techniques to children, combined with the large number of
withdrawals, may have contributed to the smaller-than-
expected improvement in PEF and FEV1 observed. In addi-
tion, variability in PEF measurements has been reported26-28
and may have resulted in under- or overestimations in the de-
tected treatment benefit in this study. Finally, it is not pos-
sible to determine whether once-daily FF is equivalent to the
standard twice-daily FP. To determine this, a noninferiority
study should be conducted.
All 3 doses of FF investigated in this study (25 mg, 50 mg,
and 100 mg) improved the change from baseline in daily predose
morning PEF in children aged 5-11 years. Notable improve-
ments over placebo were seen for all FF treatments in the per-
centage of rescue-free days. All treatments were well tolerated,
and no new safety concerns were identified during the study,
although the overall incidence of AEs was slightly greater in
active treatment groups compared with placebo. The results
of this study suggest that FF is an effective treatment for chil-
dren with inadequately controlled asthma. ■
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Excluded (n = 659)
• Not meeting inclusion criteria (n = 653)
• Withdrawal by subject (n = 4)
• Physician decision (n = 2)
Run-in failures (n = 283)
• Not meeting continuation criteria (n = 247)
• Withdrawal by subject (n = 22)
• Physician decision (n = 10)
• Lost to follow-up (n = 4)
• Other (n = 2)
– Completed the run-in period and received study 
   treatment without being randomized (n = 1) 
– Run-in period failure and not randomized (n = 1)
FF 25 (N = 118)
Completed (n = 94)
Withdrew due to:
• Lack of efficacy (n = 16)
• Investigator discretion (n = 5)
• Protocol deviation (n = 2)
• Withdrew consent (n = 1)
• Adverse event (n = 0)
• Lost to follow-up (n = 0)
• Reached protocol stopping 
  criteria (n = 0)
FF 50 (N = 120)
Completed (n = 87)
Withdrew due to:
• Lack of efficacy (n = 23)
• Withdrew consent (n = 3)
• Protocol deviation (n = 3)
• Investigator discretion (n = 2)
• Adverse event (n = 1)
• Lost to follow-up (n = 1)
• Reached protocol stopping 
  criteria (n = 0)
FF 100 (N =1 18)
Completed (n = 85)
Withdrew due to:
• Lack of efficacy (n = 21)
• Investigator discretion (n = 4)
• Withdrew consent (n = 4)
• Adverse event (n = 2)
• Protocol deviation (n = 1)
• Lost to follow-up (n = 1)
• Reached protocol stopping 
  criteria (n = 0)
FP 100 (N=118)
Completed (n = 89)
Withdrew due to:
• Lack of efficacy (n = 19)
• Withdrew consent (n = 3)
• Protocol deviation (n = 3)
• Investigator discretion (n = 2)
• Adverse event (n = 1)
• Lost to follow-up (n = 1)
• Reached protocol stopping 
  criteria (n = 0)
Placebo (N = 119)
Completed (n = 66)
Withdrew due to:
• Lack of efficacy (n = 42)
• Withdrew consent (n = 4)
• Investigator discretion (n = 3)
• Protocol deviation (n = 1)
• Adverse event (n = 1)
• Lost to follow-up (n = 1)
• Reached protocol stopping 
  criteria (n = 1)
Assessed for eligibility
(N = 1540)
Intention-to-treat
population (N = 593)
Randomized (N = 596)
Entered run-in (N = 881)
Randomized but did not receive 
study medication (N = 3)
Figure 1. CONSORT flow diagram. Lack of efficacy was defined as experiencing an exacerbation, worsening asthma, or at
the investigator’s discretion.
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Figure 2. Mean changes from baseline in morning PEF averaged over weeks 1-12 (L/min). Error bars represent SE. LS, least
squares.
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Figure 3. UC excretion (24-hour) at baseline and at week 12 (UC population). BD, twice daily; OD, once daily.
Table III. Post hoc analysis of change from baseline in evening trough FEV1, week 12 (LOCF)
Placebo, n = 119 FF 25 OD, n = 118 FF 50 OD, n = 120 FF 100 OD, n = 118 FP 100 BD, n = 118
Acceptable baseline and last on-treatment FEV1
n 65 63 70 56 71
LS mean, L 1.535 1.680 1.608 1.626 1.698
LS mean change, mL (SE) 79 (31) 224 (32) 152 (30) 170 (34) 242 (30)
Treatment vs placebo
Difference, mL 145 73 91 163
95% CI 57, 223 −14, 159 1, 181 77, 249
By age subgroup
5-7 y
n 38 35 27 41 42
LS mean, L 1.249 1.218 1.188 1.191 1.206
LS mean change, mL (SE) 163 (37) 132 (39) 102 (44) 105 (37) 120 (34)
Treatment vs placebo
Difference, mL −31 −61 −58 −43
95% CI −137, 75 −174, 53 −161, 46 −142, 56
8-11 y
n 64 61 85 55 60
LS mean, L 1.671 1.883 1.755 1.763 1.811
LS mean change, mL (SE) 102 (36) 313 (37) 186 (31) 194 (39) 241 (37)
Treatment vs placebo
Difference, mL 211 84 92 140
95% CI 110, 313 −10, 177 −12, 195 38, 241
LS, least squares; BD, twice daily; OD, once daily.
Table V. UC excretion at week 12 (UC population)*
Placebo,
n = 54
FF 25 OD,
n = 75
FF 50 OD,
n = 73
FF 100 OD,
n = 73
FP 100 BD,
n = 73
n 54 75 73 73 73
LS geometric mean 34.19 30.46 34.00 30.74 30.70
LS ratio to baseline 1.07 0.95 1.06 0.96 0.96
Treatment vs placebo
Ratio 0.89 0.99 0.90 0.90
95% CI 0.70, 1.13 0.78, 1.26 0.71, 1.14 0.71, 1.14
P value .340 .963 .377 .369
*Includes outlier.
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